TrialBMC cancer2011

A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study.

Elaine S Rogers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.